Comparing CJC-1295 with DAC and CJC-1295 without DAC plus ipamorelin head-to-head for two weeks each is a potential trial.

“This is what most clinicians prescribe and most of the peptide community uses. The tradeoff: less clinical trial data, daily injections, more anecdotal evidence base.”

“What we're considering: Start with DAC at half dose 2.4 mg, then if well tolerated escalate 4.8 mg, weekly injection. If side effects aren't tolerable, switch to no-DAC + ipamorelin (100 mcg then 200-300 mcg daily, before bedtime).”

“Or, Run both head to head. 2 weeks DAC, 2 weeks no-DAC + ipamorelin and compare.”